Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The main role of early phase clinical trials in cancer is to determine the dose to take forward for future clinical study. However, study design is changing in order to account for the change in focus of drug development toward molecularly targeted agents.

Original publication

DOI

10.12968/hmed.2015.76.7.409

Type

Journal article

Journal

Br J Hosp Med (Lond)

Publication Date

07/2015

Volume

76

Pages

409 - 413

Keywords

Antineoplastic Agents, Clinical Trials, Phase I as Topic, Dose-Response Relationship, Drug, Humans, Maximum Tolerated Dose, Neoplasms